Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)

Interventions

DRUG: DSB2455

Sponsor

Duke Street Bio Ltd